Investigates the anti-allergic effects of Bambusae Caulis in Taeniam in mast cells and allergic responses, indicating its potential therapeutic use.
Bambusae Caulis in Taeniam (BCT) has traditionally been used to relieve vomiting, febrile symptoms, and mucosal irritation, whereas its anti-allergic mechanisms remain poorly understood. In this study, the anti-allergic activity of BCT was assessed in vivo using the passive cutaneous anaphylaxis (PCA) model and in vitro using MC/9 mast cells. Oral administration of BCT significantly reduced Evans blue extravasation in PCA mice, indicating inhibition of immunoglobulin E (IgE)-mediated immediate hypersensitivity. In MC/9 cells, BCT dose-dependently suppressed PMA/A23187-induced secretion of histamine, prostaglandin E2 (PGE2), and tumor necrosis factor-α (TNF-α). Mechanistically, BCT inhibited the phosphorylation of mitogen-activated protein kinases (JNK, ERK, and p38) and reduced nuclear factor κB (NF-κB) mRNA expression. These findings suggest that BCT mitigates immediate allergic responses by modulating mast cell activation and key inflammatory signaling pathways, supporting its potential as a natural anti-allergic agent.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: